SGLT2 Inhibitors and Their Role in Reducing Hospitalization in Chronic Heart Failure
DOI:
https://doi.org/10.62497/irjm.207Keywords:
SGLT2, chronic heart failure, hospitalization, cardiovascular, cohort studyAbstract
Introduction: The condition of chronic heart failure is characterized by a high rate of morbidity and intensive hospital admission despite the increase in treatment. SGLT2 inhibitors have become a new therapeutic agent that holds potential cardiovascular advantages to glycemic control. The aim of the study was to determine their effectiveness in the minimization of hospitalization in patients with chronic heart failure.
Methodology: A proposal was an observational cohort study at Khalifa Gul Nawaz Teaching Hospital, Bannu in a sample size of 320 patients with chronic heart failure. The patients were separated into two groups having SGLT2 inhibitors and normal therapy. The findings were recorded over a period of six months and the results such as the rates of hospitalization were tested by use of chi-square test, independent t-test, Kaplan-Meier test and multivariate logistic regression.
Results: In the SGLT2 group, hospitalization was seen in 21.3 percent of patients as compared to 42.5 percent in the non-SGLT2 group (p < 0.001). Kaplan-Meier established that time to hospitalization was much later in SGLT2 group (p < 0.001). The use of SGLT2 inhibitor was a predictor of a reduction in hospitalization (AOR = 0.38, p < 0.001). There was a tendency towards a decreased mortality, but it was not significant.
Conclusion: SGLT2 inhibitors were found to decrease the risk of hospitalization in chronic heart failure considerably and must be regarded as a valuable part of the regular treatment.
References
Cardoso R, Graffunder FP, Ternes CM, Fernandes A, Rocha AV, Fernandes G, Bhatt DL. SGLT2 inhibitors decrease cardiovascular death and heart failure hospitalizations in patients with heart failure: a systematic review and meta-analysis. EClinicalMedicine. 2021 Jun 1;36.
Vaduganathan M, Docherty KF, Claggett BL, Jhund PS, de Boer RA, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CS, Martinez F, Shah SJ. SGLT2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. The Lancet. 2022 Sep 3;400(10354):757-67.
Blanco CA, Garcia K, Singson A, Smith WR. Use of SGLT2 inhibitors reduces heart failure and hospitalization: a multicenter, real-world evidence study. The Permanente Journal. 2023 Mar 13;27(1):77.
Muscoli S, Barilla F, Tajmir R, Meloni M, Della Morte D, Bellia A, Di Daniele N, Lauro D, Andreadi A. The new role of SGLT2 inhibitors in the management of heart failure: current evidence and future perspective. Pharmaceutics. 2022 Aug 18;14(8):1730.
Kommu S. The role of SGLT2 inhibitors on heart failure outcomes in nondiabetic patients: a systematic review and meta-analysis of randomized controlled trials. Journal of Cardiovascular Pharmacology. 2024 Feb 1;83(2):158-66.
Zannad F, Ferreira JP, Pocock SJ, Anker SD, Butler J, Filippatos G, Brueckmann M, Ofstad AP, Pfarr E, Jamal W, Packer M. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. The Lancet. 2020 Sep 19;396(10254):819-29.
Palmiero G, Cesaro A, Vetrano E, Pafundi PC, Galiero R, Caturano A, Moscarella E, Gragnano F, Salvatore T, Rinaldi L, Calabrò P. Impact of SGLT2 inhibitors on heart failure: from pathophysiology to clinical effects. International Journal of Molecular Sciences. 2021 May 30;22(11):5863.
Tsampasian V, Baral R, Chattopadhyay R, Debski M, Joshi SS, Reinhold J, Dweck MR, Garg` P, Vassiliou VS. The role of SGLT2 inhibitors in heart failure: a systematic review and meta‐analysis. Cardiology research and practice. 2021;2021(1):9927533.
Crispino SP, Segreti A, Nafisio V, Valente D, Crisci F, Ferro A, Cavallari I, Nusca A, Ussia GP, Grigioni F. The role of SGLT2-inhibitors across all stages of heart failure and mechanisms of early clinical benefit: from prevention to advanced heart failure. Biomedicines. 2025 Mar 3;13(3):608.
Voors AA, Angermann CE, Teerlink JR, Collins SP, Kosiborod M, Biegus J, Ferreira JP, Nassif ME, Psotka MA, Tromp J, Borleffs CJ. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nature medicine. 2022 Mar;28(3):568-74.
Ul Amin N, Sabir F, Amin T, Sarfraz Z, Sarfraz A, Robles-Velasco K, Cherrez-Ojeda I. SGLT2 inhibitors in acute heart failure: a meta-analysis of randomized controlled trials. InHealthcare 2022 Nov 23 (Vol. 10, No. 12, p. 2356). MDPI.
Chen J, Jiang C, Guo M, Zeng Y, Jiang Z, Zhang D, Tu M, Tan X, Yan P, Xu X, Long Y. Effects of SGLT2 inhibitors on cardiac function and health status in chronic heart failure: a systematic review and meta-analysis. Cardiovascular Diabetology. 2024 Jan 3;23(1):2.
van der Aart-van der Beek AB, de Boer RA, Heerspink HJ. Kidney and heart failure outcomes associated with SGLT2 inhibitor use. Nature Reviews Nephrology. 2022 May;18(5):294-306.
Talha KM, Anker SD, Butler J. SGLT-2 inhibitors in heart failure: a review of current evidence. International Journal of Heart Failure. 2023 Mar 13;5(2):82.
Bazoukis G, Papadatos SS, Thomopoulos C, Tse G, Cheilidis S, Tsioufis K, Farmakis D. Impact of SGLT2 inhibitors on major clinical events and safety outcomes in heart failure patients: a meta-analysis of randomized clinical trials. Journal of Geriatric Cardiology: JGC. 2021 Oct 28;18(10):783.
Amioka M, Sanada R, Matsumura H, Kinoshita H, Sairaku A, Morishima N, Nakano Y. Impact of SGLT2 inhibitors on old age patients with heart failure and chronic kidney disease. International Journal of Cardiology. 2023 Jan 1;370:294-9.
Gao M, Bhatia K, Kapoor A, Badimon J, Pinney SP, Mancini DM, Santos-Gallego CG, Lala A. SGLT2 inhibitors, functional capacity, and quality of life in patients with heart failure: a systematic review and meta-analysis. JAMA Network Open. 2024 Apr 4;7(4):e245135.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Syed Awais Ali Shah , Akasha Maqsood, Yashal Naveed, Arif Ullah , Muhammad Irfan Ullah, Atif ullah khan (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
